Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus BUTENAFINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus BUTENAFINE HYDROCHLORIDE.
AMPHOTEC vs BUTENAFINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
Category C
Category C
Antifungal
Antifungal